| |  Online-Ressource |
|---|
| Verfasst von: | Trojan, Andreas [VerfasserIn]  |
|---|
| | Tinguely, Marianne [VerfasserIn] |
|---|
| | Vallet, Sonia [VerfasserIn] |
|---|
| | Seifert, Burkhardt [VerfasserIn] |
|---|
| | Jenni, Bettina [VerfasserIn] |
|---|
| | Zippelius, Alfred [VerfasserIn] |
|---|
| | Witzens-Harig, Mathias [VerfasserIn] |
|---|
| | Mechtersheimer, Gunhild [VerfasserIn] |
|---|
| | Ho, Anthony Dick [VerfasserIn] |
|---|
| | Goldschmidt, Hartmut [VerfasserIn] |
|---|
| | Jäger, Dirk [VerfasserIn] |
|---|
| | Boccadoro, Mario [VerfasserIn] |
|---|
| | Ladetto, Marco [VerfasserIn] |
|---|
| Titel: | Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma |
|---|
| Verf.angabe: | Andreas Trojan, Marianne Tinguely, Sonia Vallet, Burkhardt Seifert, Bettina Jenni, Alfred Zippelius, Mathias Witzens-Harig, Gunhild Mechtersheimer, Anthony D. Ho, Hartmut Goldschmidt, Dirk Jäger, Mario Boccadoro, Marco Ladetto |
|---|
| E-Jahr: | 2006 |
|---|
| Jahr: | [2006] |
|---|
| Umfang: | 4 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Gesehen am 15.02.2022 |
|---|
| Titel Quelle: | Enthalten in: Swiss medical weekly |
|---|
| Ort Quelle: | Basel : EMH Schweizerischer Ärzteverl., 1996 |
|---|
| Jahr Quelle: | 2006 |
|---|
| Band/Heft Quelle: | 136(2006), 25/26, Seite 400-403 |
|---|
| ISSN Quelle: | 1424-3997 |
|---|
| Abstract: | Several biological and clinical considerations suggest the involvement of cyclooxygenase-2 (COX-2), the key enzyme of prostaglandin (PG) synthesis, in the pathogenesis and progression of haematological malignancies. Despite the wealth of data concerning COX-2 expression, only limited information is available on multiple myeloma (MM). Using standard immunohistochemistry we therefore evaluated COX-2 protein expression in samples from 57 patients with a primary diagnosis of MM. Time to progression and a variety of clinicopathological features were evaluated by the Kaplan-Meier method and the Cox regression model. In addition, COX-2 expression was evaluated by staining bone marrow from healthy donors and 11 patients with MGUS. Overall, 31 MM samples (54%) expressed COX-2. Positivity for COX-2 was unrelated to stage or clinical or molecular features of the disease. However, patients with COX-2 positive tumours experienced a significantly shorter time to progression (17 vs 30 months, p = 0.037). In summary, COX-2 is frequently expressed in MM and correlates with shorter progression-free survival. |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://serval.unil.ch/resource/serval:BIB_F68233E85238.P001/REF |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Adult |
|---|
| | Aged |
|---|
| | Aged, 80 and over |
|---|
| | Cyclooxygenase 2 |
|---|
| | Disease Progression |
|---|
| | Female |
|---|
| | Humans |
|---|
| | Immunohistochemistry |
|---|
| | Male |
|---|
| | Middle Aged |
|---|
| | Multiple Myeloma |
|---|
| | Proportional Hazards Models |
|---|
| | Survival Analysis |
|---|
| K10plus-PPN: | 1789610109 |
|---|
| Verknüpfungen: | → Zeitung |
|---|
Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma / Trojan, Andreas [VerfasserIn]; [2006] (Online-Ressource)
